Patient-physician Discussions Research Articles

A Large Percentage of Excision Specimens Show Residual Basal Cell Carcinoma: A Retrospective Chart Review.

Treatment of basal cell carcinoma (BCC) is recommended. However, patients often note that the biopsy site appears resolved and inquire about the need for additional treatment. This study aims to determine the rate of residual BCC on excision specimens after initial shave biopsy to aid in decision-making on the necessity of further treatment. A retrospective chart review was conducted that reviewed excision specimen pathology reports of previously biopsy-proven basal cell carcinomas for the presence of residual tumor between 2012 and 2022 at a single institution. Two thousand one hundred seventeen cases met inclusion criteria. Overall, 39.4% of patients had residual BCC after an initial shave biopsy. Using an odds ratio and 95% confidence interval, a significant relationship was found between larger lesions, longer time between biopsy and excision, and lesions on high-risk body sites with increased odds of residual BCC. A significant relationship was found between negative or not specified margins on shave biopsy with decreased odds of residual BCC. The results show that a large percentage of patients have residual BCC following initial biopsies. These results should be included in physician-patient discussions about treatment options for BCC.

Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals.

Aim: Erectile dysfunction (ED) is marked by a recurring incapacity to achieve or uphold a satisfactory erection during sexual activities. The study aims to increase awareness about male reproductive health, dispel misconceptions about ED and encourage physician-patient discussions. Materials & methods: A live online poll was conducted during a 3-day webinar titled "Turning the Tide of Men's Health" organized by Viatris™ in collaboration with the Saudi Society of Family and Community Medicine and attended by healthcare professionals (HCPs) from diverse specialties. The attendees voluntarily responded to nine poll questions on adherence to ED medication, use of phosphodiesterase type 5 inhibitors (PDE5is) as cure versus management of ED and patients' challenges. The responses to the poll questions were recorded and assessed to understand the perceptions of HCPs. Results: The poll garnered 10,423 responses from 5831 attendees on the second day of the webinar. The key findings included HCPs' perceptions that PDE5is contribute to ED management not complete cure. The respondents acknowledged that adherence to ED medications might decline on days without planned sexual activity, and long-term adherence on a daily PDE5i is exhibited by a relatively modest percentage of ED patients. The consensus among respondents was that PDE5is do not enhance or generate sexual desire, and the daily schedule of ED treatment may be burdensome for some patients. Conclusion: The findings from this poll offer insights into the perspectives of HCPs regarding the usage of PDE5is to treat ED. Responders of the poll generally agreed that PDE5is can help manage ED without affecting desire, though adherence may be lower on days without planned sexual activity. Furthermore, most respondents acknowledged that adhering to a daily pill regimen posed a greater burden than waiting for the medication to take effect.

Posterior Nasal Nerve Ablation as a Viable Treatment Option for the Primary Symptom of Postnasal Drip.

Postnasal drip (PND) syndrome is a prevalent complaint encountered in otolaryngology practices. PND may be refractory to medical therapy, and surgical treatments are complicated by side effects. While posterior nasal nerve (PNN) ablation has demonstrated efficacy for chronic rhinitis overall, we sought to examine the effect of PNN ablation for patients with PND as their primary complaint. This is a retrospective case series study of 40 chronic rhinitis (CR) patients with a primary complaint of PND. Included patients had to have failed medical therapy such as anti-cholinergic nasal sprays, reflux treatments, and/or nasal steroids. Primary outcome measures included 22 item Sino-Nasal Outcome Test (SNOT-22) PND component and Total Nasal Symptom Score. Secondary outcome measure was subjective improvement, defined as a > 30% improvement in PND symptoms. Median follow-up was 138 days (interquartile range: 72-193). 72.5% (29/40) of patients reported at least a 30% improvement in PND symptoms. Mean PND SNOT-22 scores were 4.2/5 (SD = 0.8) pre-procedure versus 1.9/5 (SD = 1.3) post-procedure (P = .001). PNN ablation response did not correlate to ipratropium bromide nasal spray response, although younger and non-smoker patients had better response rates. This exploratory study of PNN ablation for the primary symptom of PND demonstrates efficacy as assessed by the PND component of SNOT-22 and subjective improvement. These results can be useful in guiding physician-patient discussions in determining treatment options for medically refractory PND.

Pilot study evaluating the usability of MonŒil, a ChatGPT-based education tool in ophthalmology

ImportanceThere is an increasing use of artificial intelligence (AI) in ophthalmology to respond to the needs of patients to access reliable, easy-to-understand medical information. ObjectiveTo assess patient satisfaction with the usability of MonŒil, an AI-based platform designed for patient education in ophthalmology. DesignThis was a pilot cross-sectional study of the usability of MonŒil by patients followed for advanced age-related macular degeneration (AMD). MonŒil is based on ChatGPT-4 technology with specific ophthalmology-focused customizations and accessibility enhancements, and is freely available at monoeil.help. Patients were given 20 min of unsupervised interaction with no prior training or guidance, after which their feedback was collected. SettingThe study was performed in the ophthalmology department at the Creteil University Hospital. ParticipantsParticipants included 54 patients diagnosed with advanced AMD defined presenting for follow-up. Patients had to be older than 50 years of age, capable of giving informed consent, and able to understand and interact with MonŒil. Exclusion criteria were severe visual and cognitive impairment that prevented interaction with MonŒil. Main Outcome(s) and Measure(s)The primary outcome was the usability of MonŒil as measured by the System Usability Scale (SUS) questionnaire. ResultsOf the 54 participants, 34 were female (62.96 %). The mean age of the cohort was 77.76±8.14 years (range 58 to 97 years). The mean SUS score was 90.23±12.04 with a median of 92.50 (range 42.50 to 100.00), indicating excellent usability. There was a positive relationship between visual acuity and SUS score (regression coefficient 0.30 (95 % CI 0.08 to 0.51), r2=0.19, p = 0.0077). Conclusions and RelevanceMonŒil demonstrated excellent usability and satisfaction in a sample population of elderly patients with advanced AMD. These results suggest that AI-based tools like MonŒil can enhance patient education with minimal oversight in a complex field like ophthalmology, supporting its use as an adjunct to the physician-patient discussion. Further studies may be necessary to establish the applicability of MonŒil to a broader user base, and to assess its usefulness and clinical impact on patient outcomes such as patient knowledge and vision-related quality of life.

Why did this happen to me? Causal attributions of illness and cultural health capital

This study examines how conversations between patients and clinicians about the causes of their health conditions relate to patient engagement in care. Leveraging cultural health capital (CHC) theory, we find that patient-physician discussions of health attributions are one mechanism to build patient understanding and activate engagement. We present a qualitative interpretive analysis of data collected in three phases with adult home health care patients: phone interviews (n = 28), field observations (n = 61), and semi-structured field interviews (n = 38). We find that engaging in discussions of causal health attributions with clinicians enables patients to overcome uncertainty, envision preventive actions, and engage in setting future goals. Such discussions must be supported by acknowledgement of the co-responsibility of individual factors and structural factors such as social determinants of health. These discussions are not easy to navigate but they can potentially help patients transition from a mindset of treating the disease (pathogenic approach) to an awareness of their available capabilities to improve health (salutogenic approach). This study contributes to research on attribution theory and cultural health capital theory by demonstrating how discussing causes for poor health can enable patients resolve doubts and accrue instrumental and symbolic resources that facilitate healing.

The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life.

Although patients with metastatic breast cancer (MBC) have been living longer with the advent of more effective treatments such as targeted therapy and immunotherapy, the disease remains incurable, and most patients will undergo therapy indefinitely. When beginning therapy, patients are typically prescribed dose often based upon the maximum tolerated dose identified in phase I clinical trials. However, patients' perspectives about tolerability and willingness to discuss individualized dosing of drugs upon initiation of a new regimen and throughout the course of treatment have not been comprehensively evaluated. Patient advocates and medical oncologists from the Patient-Centered Dosing Initiative (PCDI) developed a survey to ascertain the prevalence and severity of MBC patients' treatment-related side effects, the level of patient-physician communication, mitigation strategies, perception about the relative efficacy of higher versus lower doses, and willingness to discuss alternative dosing. The PCDI distributed the anonymous confidential online survey in August 2020 to individuals with self-reported MBC. One thousand and two hundred twenty-one patients with MBC completed the survey. 86.1% (n = 1,051) reported experiencing at least one significant treatment-related side effect, and of these, 20.3% (n = 213) visited the emergency room/hospital and 43.2% (n = 454) missed at least one treatment. Nearly all patients with side effects (97.6%, n = 1,026) informed their doctor and 81.7% (n = 838) received assistance. Of the 556 patients given a dose reduction for side-effect mitigation, 82.6% (n = 459) reported relief. Notably, majority of patients (53.3%, n = 651) do not believe that higher dose is always more effective than lower dose, and 92.3% (n = 1,127) would be willing to discuss flexible dosing options with their physicians based upon personal characteristics to optimize quality of life. Given that the majority of patients with MBC experienced at least one substantial treatment-related side effect and most patients given a dose reduction reported improvement, innovative dosage-related strategies are warranted to sustain and improve patients' well-being. Patient-physician discussions in which the patient's unique attributes and circumstances are assessed upon initiation of new treatment and throughout the course of therapy may facilitate the identification of the most favorable dose for each patient, and the majority of patients would be receptive to this approach.

Cost-of-care discussions for individuals with newly diagnosed advanced non-small cell lung cancer and melanoma: Findings from a population-based study.

3 Background: Growing costs of cancer care can result in patient financial hardship and many professional organizations, including the American Society for Clinical Oncology, recommend patient-physician discussions about expected treatment costs as part of high-quality care. Documentation of these discussions is critical as even privately insured patients may find care unaffordable without additional assistance. This study examined medical records of individuals diagnosed with advanced non-small cell lung cancer (NSCLC) and melanoma, cancers with recently approved expensive treatment options, for documentation of cost discussions. Methods: Individuals newly diagnosed 2017-2018 with stage III/IV NSCLC (n = 1767) and melanoma (n = 689) in participating SEER regions were randomly selected for the population-based National Cancer Institute Patterns of Care study. Medical records were reviewed for reported cost discussions; terms used and record location were abstracted. Patient-, treatment- and hospital- factors, including age, sex, race/ethnicity, comorbidities, and health insurance coverage, were examined for associations with cost discussions in multivariable logistic regression analyses. Results: Cost discussions were documented in the medical records of 24.6% of NSCLC and 25.5% of melanoma patients. “Out-of-pocket costs”, “patient assistance plan”, and “inability to pay” were most commonly used terms. Cost discussions were most frequently noted in physician or nursing progress notes and assessment plans. Documentation of cost discussions varied little by patient and hospital factors. In adjusted analyses, privately insured (vs. publicly insured) patients were less likely to have documented cost discussions (odds ratio (OR) = 0.54; 95% CI:0.37-0.80). Patients who did not receive systemic therapy or did not receive any cancer-directed treatment were less likely to have documented cost conversations than patients who received systemic therapy (OR = 0.39; 95% CI:0.19-0.81 and OR = 0.46; 95% CI:0.30-0.70, respectively). Conclusions: Cost discussions were infrequently documented in medical records of patient with newly diagnosed advanced NSCLC and melanoma; variability in documentation may hinder identifying this information and tracking referrals to address patients’ financial needs. The findings underscore the importance of systematic documentation of cost of care discussions to ensure high quality care for all patients.

Patient Preferences for Postmastectomy Breast Reconstruction

Up to 40% of women experience dissatisfaction after breast reconstruction due to unexpected outcomes that are poorly aligned with personal preferences. Identifying what attributes patients value when considering surgery could improve shared decision-making. Adaptive choice-based conjoint (ACBC) analysis can elicit individual-level treatment preferences. To identify which attributes of breast reconstruction are most important to women considering surgery and to describe how these attributes differ by those who prefer flap vs implant reconstruction. This web-based, cross-sectional study was conducted from March 1, 2022, to January 31, 2023, at Duke University and between June 1 and December 31, 2022, through the Love Research Army with ACBC analysis. Participants were 105 women at Duke University with a new diagnosis of or genetic predisposition to breast cancer who were considering mastectomy with reconstruction and 301 women with a history of breast cancer or a genetic predisposition as identified through the Love Research Army registry. Relative importance scores, part-worth utility values, and maximum acceptable risks were estimated. Overall, 406 women (105 from Duke University [mean (SD) age, 46.3 (10.5) years] and 301 from the Love Research Army registry [mean (SD) age, 59.2 (11.9) years]) participated. The attribute considered most important was the risk of abdominal morbidity (mean [SD] relative importance [RI], 28% [11%]), followed by chance of major complications (RI, 25% [10%]), number of additional operations (RI, 23% [12%]), appearance of the breasts (RI, 13% [12%]), and recovery time (RI, 11% [7%]). Most participants (344 [85%]) preferred implant-based reconstruction; these participants cared most about abdominal morbidity (mean [SD] RI, 30% [11%]), followed by the risk of complications (mean [SD], RI, 26% [11%]) and additional operations (mean [SD] RI, 21% [12%]). In contrast, participants who preferred flap reconstruction cared most about additional operations (mean [SD] RI, 31% [15%]), appearance of the breasts (mean [SD] RI, 27% [16%]), and risk of complications (mean [SD] RI, 18% [6%]). Factors independently associated with choosing flap reconstruction included being married (odds ratio [OR], 2.30 [95% CI, 1.04-5.08]; P = .04) and higher educational level (college education; OR, 2.43 [95% CI, 1.01-5.86]; P = .048), while having an income level of greater than $75 000 was associated with a decreased likelihood of choosing the flap profile (OR, 0.45 [95% CI, 0.21-0.97]; P = .01). Respondents who preferred flap appearance were willing to accept a mean (SD) increase of 14.9% (2.2%) chance of abdominal morbidity (n = 113) or 6.4% (4.8%) chance of complications (n = 115). This study provides information on how women value different aspects of their care when making decisions for breast reconstruction. Future studies should assess how decision aids that elicit individual-level preferences can help tailor patient-physician discussions to focus preoperative counseling on factors that matter most to each patient and ultimately improve patient-centered care.

LungCARE: Encouraging Shared Decision-Making in Lung Cancer Screening—a Randomized Trial

BackgroundLung cancer screening (LCS) is recommended for individuals at high risk due to age and smoking history after a shared decision-making conversation. However, little is known about best strategies for incorporating shared decision-making, especially in a busy primary care setting.ObjectiveTo develop a novel tool, Lung Cancer Assessment of Risk and Education (LungCARE) to guide LCS decisions among eligible primary care patients.DesignPilot cluster randomized controlled trial of LungCARE versus usual care.ParticipantsPatients of providers in a university primary care clinic, who met criteria for LCS.InterventionProviders were randomized to LungCARE intervention or control. LungCARE participants completed a computer tablet-based video assessment of lung cancer educational needs in the waiting room prior to a primary care visit. Patient and provider both received a summary handout of patient concerns and responses.Main MeasuresAll eligible patients completed baseline interviews by telephone. One week after the index visit, participants completed a follow-up telephone survey that assessed patient-physician discussion of LCS, referral to and scheduling of LCS, as well as LCS knowledge and acceptability of LungCARE. Two months after index visit, we reviewed patients’ electronic health records (EHRs) for evidence of a shared decision-making conversation and referral to and receipt of LCS.Key ResultsA total of 66 participants completed baseline and follow-up visits (34: LungCARE; 32: usual care). Mean age was 65.9 (± 6.0). Based on EHR review, compared to usual care, LungCARE participants were more likely to have discussed LCS with their physicians (56% vs 25%; p = 0.04) and to be referred to LCS (44% vs 13%; p < 0.02). Intervention participants were also more likely to complete LCS (32% vs 13%; p < 0.01) and had higher knowledge scores (mean score 6.5 (± 1.7) vs 5.5 (± 1.4; p < 0.01).ConclusionsLungCARE increased discussion, referral, and completion of LCS and improved LCS knowledge.Clinical Trial RegistrationNCT03862001.

Association of duration and intensity of exercise with phenotypic expression in hypertrophic cardiomyopathy

ObjectivesThere is limited data regarding the impact of exercise on phenotypic expression in hypertrophic cardiomyopathy (HCM). We aimed to investigate whether such an association exists in a cohort of genotype-positive HCM patients. MethodsIn this cross-sectional study of genotype-positive HCM families, we used structured questionnaires to obtain data regarding intensity and duration of exercise of participants starting at the age of 10, as well as data regarding exercise recommendations and their impact on quality of life (QOL). The association of cumulative metabolic-equivalent hours of exercise at different ages with different measures of phenotypic expression (maximal wall thickness, left atrial diameter, extent of late gadolinium enhancement) was analyzed. ResultsThe study included 109 patients from 55 families, including 43 male (39%) and 90 (83%) phenotype-positive. No association was identified between exercise duration or intensity with any of the phenotypic markers with the exception of greater cumulative exercise associated with younger age at presentation. Similar results were obtained when analysis was limited to exercise until the age of 20, until the age of 30 or only after 30.Among phenotype-positive patients, 89% recalled receiving recommendations regarding exercise restriction, 29% noted reduction in exercise level following such recommendations and 25% noted this having a significant impact on their QOL. ConclusionWe found no association between exercise intensity or duration and phenotypic expression in genotype-positive HCM patients. These findings are important for physician-patient discussions and support the recent trend towards more permissive exercise restrictions in HCM.

Female Sexual Dysfunction: A Primer for Primary Care Health Professionals.

Female sexual dysfunction (FSD) is common and associated with decreased quality of life, relationship satisfaction, and overall well-being. However, primary care practitioners report discomfort discussing, diagnosing, and treating FSD. We delivered two sessions on the approach to evaluation and treatment of FSD: a 60-minute didactic session and a 90-minute workshop. The intended audience was primary health care professionals who care for women. The workshop utilized interactive teaching methods including a large-group discussion, case-based discussions, debrief of an observed patient-physician discussion, and language drills to develop participants' knowledge and skills. Participants were surveyed about their practice patterns and attitudes toward FSD following the sessions on a 5-point Likert scale (1 = strongly disagree, 5 = strongly agree). We collected 131 evaluations from a national Veterans Health Administration 60-minute didactic and four evaluations from the Society of General Internal Medicine Annual Meeting 90-minute workshop (response rates were 60% and 15%, respectively). One hundred thirty-five interdisciplinary trainees and practitioners from both audiences highly rated the workshop content (M = 4.1) and the overall session (M = 4.3). Didactic participants (n = 131) also reported high satisfaction (M = 4.5), increased knowledge and skills (M = 4.4), and improved interprofessional collaborative practice (M = 4.4) as a result of the training. Our evaluation shows high satisfaction following interactive multimodal sessions on FSD. These adaptable resources can be used in multiple educational settings (didactic and workshop) and for multiple time frames to teach about FSD.

Use of Integrative, Complementary, and Alternative Medicine in Children with Epilepsy: A Global Scoping Review.

(1) Background: Epilepsy is one of the most common chronic neurological disorders in childhood. Complementary and alternative medicine (CAM) use is highly prevalent in patients with epilepsy. Despite CAM's widespread and increasing popularity, its prevalence, forms, perceived benefits, and potential risks in pediatric epilepsy are rarely explored. (2) Methods: We performed a scoping review of the available literature on the use of CAM in pediatric epilepsy. (3) Results: Overall, global cross-sectional studies showed a variable degree of CAM usage among children with epilepsy, ranging from 13 to 44% in prevalence. Popular types of CAMs reported were supplements, cannabis products, aromatherapy, herbal remedies, dietary therapy, massage therapy, and prayer. Families often report that CAM is effective, although there are limited objective measures of this. Potential risks lie in the use of CAM, such as herbal remedies, and/or unregulated, contaminated, or unpurified products. Studies also underscored inadequate patient-physician discussions regarding CAM. (4) Conclusions: A better understanding of this topic would aid clinicians in guiding patients/families on the use of CAM. Further studies on the efficacy of the different types of CAM used, as well as potential side effects and drug interactions are needed.

Media coverage of cancer therapeutics: A review of literature

BackgroundInformation and stories about cancer treatment are increasingly available to patients and the general public through lay media, websites, blogs and social media. While these resources may be helpful to supplement information provided during physician-patient discussions, there is growing concern about the extent to which media reports accurately reflect advances in cancer care. This review aimed to understand the landscape of published research which has described media coverage of cancer treatments. MethodsThis literature review included peer-reviewed primary research articles that reported how cancer treatments are portrayed in the lay media. A structured literature search of Medline, EMBASE and Google Scholar was performed. Potentially eligible articles were reviewed by three authors for inclusion. Three reviewers, each independently reviewed eligible studies; discrepancies were resolved by consensus. ResultsFourteen studies were included. The content of the eligible studies reflected two thematic categories: articles that reviewed specific drugs/cancer treatment (n = 7) and articles that described media coverage of cancer treatment in general terms (n = 7). Key findings include the media’s frequent and unfounded use of superlatives and hype for new cancer treatments. Parallel to this, media reports over-emphasize potential treatment benefits and do not present a balanced view of risks of side effects, cost, and death. At a broad level, there is emerging evidence that media reporting of cancer treatments may directly impact patient care and policy-making. ConclusionsThis review identifies problems in current media reports of new cancer advances – especially with undue use of superlatives and hype. Given the frequency with which patients access this information and the potential for it to influence policy, there is a need for additional research in this space in addition to educational interventions with health journalists. The oncology community – scientists and clinicians – must ensure that we are not contributing to these problems.

O.O.7.3 - Spoken Plain Language Strategies in Patient-Physician Discussions of Cancer Clinical Trials: Presenter(s): Luke Thominet, Florida International University, United States

O.O.7.3 - Spoken Plain Language Strategies in Patient-Physician Discussions of Cancer Clinical Trials: Presenter(s): Luke Thominet, Florida International University, United States

Living with Type 2 Diabetes: Podcast of a Patient-Physician Discussion.

For patients with type 2 diabetes (T2D), the journey to diagnosis may not be straightforward. Patients can present with one of many diabetic complications before a diagnosis of T2D is made. These include heart disease and chronic kidney disease, in addition to cerebrovascular disease, peripheral vascular disease, retinopathy, and neuropathies, all of which can be asymptomatic in the early stages. In their clinical guidelines on standards of care in diabetes, the American Diabetes Association recommends regular screening for conditions such as kidney disease in patients with T2D. Furthermore, the frequent coexistence of diabetes and cardiorenal and/or metabolic conditions often requires a holistic approach to patient management, with specialists from multiple disciplines, including cardiologists, nephrologists, endocrinologists, and primary care physicians, working together. In addition to the use of pharmacological therapies, which can improve prognosis, the management of T2D should include attention to patient self-care, including appropriate dietary changes, consideration of continuous glucose monitoring, and advice on physical exercise. In this podcast, a patient and a clinician discuss a lived experience of the diagnosis of T2D, and the importance of patient education for understanding and managing T2D and its complications. The discussion highlights the central role of the Certified Diabetes Care and Education Specialist, and the role of ongoing emotional support in managing life with T2D, including patient education through reputable online resources and peer support groups. Podcast video with Pamela Kushner (PK) and Anne Dalin (AD) (MP4 92088 KB).

Documentation quality of patient-directed discharge and early warning interactions in an adult inpatient service.

Documentation quality of patient-physician discussion, assessment, and intervention at the time of patient directed discharges (elopement and 'against medical advice' discharges) is found to be poor in available studies, and importantly, may be a proxy for quality of care delivered. Less is known about the patient-physician interactions and documentation at the time a patient vocalizes the desire to leave early ('early warning interaction') prior to a patient directed discharge. This was a cohort study comprising a retrospective chart review of patients leaving 'against medical advice' from an inpatient internal medicine - infectious disease service at a tertiary medical center from 07/01/2020 to 09/24/2021. Documentation quality was assessed using 11 extractable factors detailing patient-physician conversation elements from the AIMED framework, plus related interventions pertinent to patient safety and care optimization. Descriptive statistics were mainly utilized with inferential statistics and regression models as appropriate. 52 patients left against medical advice and 49 eloped; 11% had an early warning interaction. Aggregate documentation quality scores at early warning interaction (13%), 'against medical advice' discharge (42%), and at elopement (31%) were low. Half of suggested documentation elements were recorded in no patients. Documentation quality overall was poor, suggesting the need for further training and interventions to facilitate more thorough documentation.

Knowledge and Practice Regarding Risk Factors for Peptic Ulcer Disease in Saudi Arabia’s Adult Population

Objective: To assess the knowledge of the Saudi population on peptic ulcer diseases (PUD) and their risk factors. To evaluate their awareness and practices of the preventive methods used in daily practic-es. Methods: This was an online cross-sectional survey that included residents of all five regions of Saudi Arabia regardless of nationality. The survey was distributed in both the Arabic and English languages to approach more individuals from different backgrounds. Results: There were 784 participants, of which 6.1% non-Saudis and 93.9% were Saudis. 63.5 % of participants selected “H. Pylori” as a risk factor that may lead to PUD. Among other risk factors, 39.2% selected smoking and 37.5% selected NSAIDs. There was a statistically significant correlation (p=0.03) between a question about knowing what H. pylori are and the respondents' level of education, with 77.3% of respondents with a high school diploma answering "No" and 63% of respondents with a postgraduate degree answering "Yes". Only 32.8% of the participants knew about H. Pylori, when hands are not washed after using the restroom or before eating or preparing food, pylori can spread. 56% of respondents were unaware that NSAIDs should be taken with or after a meal. In addition, on-ly 50% of smokers were aware that smoking contributed to the pathogenesis of PUD. Conclusion: This research revealed that very little is known about H. Pylori and how it spreads, as well as the adverse effects of NSAIDs and the precautions that must be taken to avoid them. This demon-strates the need for public education about these risk factors and the diseases they may cause, as well as the significance of physician-patient discussions to ensure patients have the necessary knowledge prior to starting NSAID therapy.

Assessing Surgical Approaches for Acoustic Neuroma Resection: Do Patients Perceive a Difference in Quality-of-Life Outcomes?

The objective of this study is to further patient-physician discussion regarding postoperative quality of life expectations after surgical acoustic neuroma resection. This study is retrospective prospective. Qualifying patients were identified and administered Penn Acoustic Neuroma Quality-of-Life (PANQOL) Scale. The setting was Loyola University Chicago Health System. Three hundred twenty-six patients at our center with surgically resected acoustic neuroma between January 1990 and July 2021 completed the PANQOL. During postresection follow-up visits, patients were administered the PANQOL survey. The total PANQOL is comprised of questions addressing quality of life in seven domains of hearing, balance, face, energy, pain, health, and anxiety. Univariate and multivariable analyses were performed to test for associations between surgical approach and/or patient characteristics. Patients who were treated with retrosigmoid approach reported slightly higher PANQOL pain scores when compared with translabyrinthine approach. No association was found between responses on hearing PANQOL and surgical approach. No association was found between approach and total PANQOL score. However, on average female patients reported lower total PANQOL compared with male patients. The lack of association between patient response on hearing PANQOL and surgical approach illustrates the impact of preoperative patient counseling in appropriately setting patient expectations. The difference in pain PANQOL response may be due to a higher rate of occipital neuralgia due to incision placement and soft tissue retraction in the retrosigmoid patient group. Surgeons may consider alternative surgical incisions and soft tissue dissection to improve patient's quality of life with respect to postoperative pain.

Ethical Approach for Managing Patient-Physician Conflict and Ending the Patient-Physician Relationship: ACOG Committee Statement No. 3.

Physicians have an ethical obligation to foster a therapeutic alliance with their patients. If the therapeutic relationship becomes strained, physicians should attempt to resolve the conflict, when possible, through intentional patient-physician discussion or through a third-party mediator. If return to a therapeutic relationship is not possible or mutually desirable, ending the patient-physician relationship may be the best option for the patient and the physician. This Committee Statement provides an ethical framework for managing patient-physician conflict and evidence-based tools and interpersonal interventions to help rebuild meaningful connection with patients. Guidance for the ethical termination of care when the therapeutic alliance cannot be restored also is provided, including institutional responsibilities to patients and physicians.

Chronic-Phase Chronic Myeloid Leukemia Times to Death By Disease Support Tyrosine Kinase Inhibitor Dose Reductions When BCR::ABL1 Level Is

Tyrosine kinase inhibitors (TKIs) are commonly believed to provide almost-normal lifespans to patients with chronic-phase (CP) chronic myeloid leukemia (CML). This is, however, not supported by Surveillance, Epidemiology, and End Results (SEER) mortalities >10 years after diagnoses that reveal a CP-CML relative risk (RR) of death of 2.14 (95% confidence interval [CI], 1.97-2.32); normal lifespans yield RR = 1.00, and by 10 years after diagnoses, most CML patients still alive were in CP at diagnosis, dates of which were between 2001 and 2009. This CP-CML RR estimate of 2.14 is comparable to those of Hodgkin's lymphoma (2.08; 95% CI, 1.95-2.22) and acute myeloid leukemia (2.22; 95% CI, 1.99-2.47) and higher than those of non-Hodgkin's lymphoma (1.62; 95% CI, 1.59-1.65) and chronic lymphocytic leukemia (1.84; 95% CI, 1.79-1.9). Thus, CP-CML is not functionally cured. In contrast, the RRs of hairy cell leukemia (1.14; 95% CI, 0.98-1.31) and acute promyelocytic leukemia (1.15; 95% CI, 0.87-1.49) are consistent with these leukemias being functionally cured. Of excess CP-CML deaths, roughly two thirds were by disease. These excess deaths by disease may be due in part to prolonged dose interruptions in response to treatment-related toxicities or to reduce financial burdens (ie, absence of TKI therapy). Frequencies of such events, and thus deaths by disease, could be decreased by reducing TKI doses moderately as cancer loads fall low enough to pose negligible progression risks. We present CML-intrinsic, TKI-agnostic support for reducing TKI doses when BCR::ABL1IS is <1% and decreasing. Times from diagnosis to death for 2732 SEER patients with CML diagnosed between 1975 and 1985 (before the availability of TKIs) informed a Markov model of CP → accelerated phase → blast crisis → death that assumed CML-saturated marrows in the absence of disease-modifying therapies during this time. The probabilities of transitioning from each phase to the next were fitted to the excess absolute risk of death (compared with the general US population) as a function of years after diagnosis (Panel A). To predict TKI effects on the probability of death by disease, the chronic-to-accelerated phase transition rate was assumed to be proportional to TKI-induced reductions in CML load fraction L, due to the reduced number of leukemic cells susceptible to a transforming mutation. Reducing L by a factor of 10 (from 1 to 0.1) increased the amount of time needed to reach a 5% probability of death by disease from 1 to 3 years. Lowering L by an additional factor of 10 (to 0.01 [1%]) increased the expected number of years to 16 (ie, ~5-fold). Finally, a third reduction of L by a factor of 10 (to 0.001 [0.1%]) yielded nearly an additional 10-fold increase in the time needed to reach a 5% probability of death by disease, from 16 to 145 years (Panel B). Gains in relative delay in 5% probability of death by disease divided by relative decrease in L were maximal at L = 0.015, which can be argued to correspond to BCR::ABLIS = 0.75% = ~1%, which appears to be a point of departure in Panel B. Based on data that predates TKIs, our analysis suggests that there is a strong need to lower disease burdens (BCR::ABLIS) below 1% and essentially no need to lower them below 0.1%. Thus, while it is important to use drug dosing that maintains responses at 1% or lower, if BCR::ABLIS is <1% and decreasing, dose reductions should be considered. Such reductions may prevent deaths associated with mismanagement of drug directly and deaths by disease indirectly, as reducing doses prospectively may avoid toxicities that may otherwise result in prolonged interruptions that cause to rise enough to cause death by disease. These dose reduction benefits should be included in patient-physician discussions of pursuing lower BCR::ABLIS levels in hopes of achieving a treatment-free remission versus pursuing lower doses to mitigate toxicity risks. Envisioned here is a future in which personalized patient safety parameters are weighed against personalized predictions of BCR::ABLIS response dynamics that, through computer simulations incorporating our Markov model, project to risks of progression and death by disease. Decision support based on such models may help patients and physicians balance drug versus disease risks. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal